Alzheimers Research & Therapy

Article	Citations
Comparing a pre-defined versus deep learning approach for extracting brain atrophy patterns to predict cognitive decline due to Alzheimer’s disease in patients with mild cognitive symptoms	547
Retraction Note: Increased Aβ42-α7-like nicotinic acetylcholine receptor complex level in lymphocytes is associated with apolipoprotein E4-driven Alzheimer’s disease pathogenesis	166
Diabetes status, duration, and risk of dementia among ischemic stroke patients	151
APOE4 carrier status determines association between white matter disease and grey matter atrophy in early-stage dementia	149
Targeting early tau pathology: probiotic diet enhances cognitive function and reduces inflammation in a preclinical Alzheimer’s model	127
Exploring sex differences in Alzheimer’s disease: a comprehensive analysis of a large patient cohort from a memory unit	117
Is the clinical phenotype impact the prognosis in dementia with Lewy bodies?	113
Kidney function, albuminuria, and their modification by genetic factors and risk of incident dementia in UK Biobank	109
Experiences of and recommendations on clinical trial design in Alzheimer’s disease from the participant’s point of view: a mixed-methods study in two clinical trial centers in the Netherlands	98
Association of outer retinal and choroidal alterations with neuroimaging and clinical features in posterior cortical atrophy	91
Blood biomarkers and neurodegeneration in individuals exposed to repetitive head impacts	87
The course of primary progressive aphasia diagnosis: a cross-sectional study	86
Clinical features and biomarkers of semantic variant primary progressive aphasia with MAPT mutation	80
Longitudinal change in ATN biomarkers in cognitively normal individuals	79
Molecular landscape of the overlap between Alzheimer’s disease and somatic insulin-related diseases	79
Prognostic model for predicting Alzheimer’s disease conversion using functional connectome manifolds	78
Intestinal endogenous metabolites affect neuroinflammation in 5×FAD mice by mediating “gut-brain” axis and the intervention with Chinese Medicine	78
The impact of incident stroke on cognitive trajectories in later life	76
Rationale and study design of a randomized, placebo-controlled, double-blind phase 2b trial to evaluate efficacy, safety, and tolerability of an oral glutaminyl cyclase inhibitor varoglutamstat (PQ912	71
Gossypetin ameliorates 5xFAD spatial learning and memory through enhanced phagocytosis against Aβ	69
Association of accelerated long-term forgetting and senescence-related blood-borne factors in asymptomatic individuals from families with autosomal dominant Alzheimer’s disease	67
Lower activity of cholesteryl ester transfer protein (CETP) and the risk of dementia: a Mendelian randomization analysis	66
Retinal optical coherence tomography intensity spatial correlation features as new biomarkers for confirmed Alzheimer’s disease	66
Plasma Hepcidin as a potential informative biomarker of Alzheimer disease and vascular dementia	65
Investigating the Aβ and tau pathology in autosomal dominant Alzheimer’s disease: insights from hybrid PET/MRI and network mapping	65

Association and multimodal model of retinal and blood-based biomarkers for detection of preclinical Alzheimer’s disease	61
Association between treatment with sacubitril/valsartan and the risk of Alzheimer’s disease: a clinical update	60
Mesial temporal tau in amyloid-β-negative cognitively normal older persons	60
Cerebrospinal fluid β2-microglobulin promotes the tau pathology through microglia–astrocyte communication in Alzheimer's disease	59
Alzheimer’s pathology is associated with altered cognition, brain volume, and plasma biomarker patterns in traumatic encephalopathy syndrome	59
Uncovering the epigenetic regulatory clues of PRRT1 in Alzheimer’s disease: a strategy integrating multi-omics analysis with explainable machine learning	59
Exploring shared neural substrates underlying cognition and gait variability in adults without dementia	56
Longitudinal evaluation of neuroinflammation and oxidative stress in a mouse model of Alzheimer disease using positron emission tomography	55
Investigating the power of eyes open resting state EEG for assisting in dementia diagnosis	54
Chemical genetic activation of the cholinergic basal forebrain hippocampal circuit rescues memory loss in Alzheimer’s disease	52
Cornuside alleviates cognitive impairments induced by Aβ1−42 through attenuating NLRP3-mediated neurotoxicity by promoting mitophagy	50
Tau-PET pathology in the subregions of the amygdala and its associations with cognitive performance and neuropsychiatric symptoms in autosomal dominant Alzheimer’s disease	49
Synergistic interaction of high blood pressure and cerebral beta-amyloid on tau pathology	49
Plasma amyloid-β oligomerization assay as a pre-screening test for amyloid status	48
A cross-sectional study in healthy elderly subjects aimed at development of an algorithm to increase identification of Alzheimer pathology for the purpose of clinical trial participation	48
A novel age-informed approach for genetic association analysis in Alzheimer’s disease	48
An association of CSF apolipoprotein E glycosylation and amyloid-beta 42 in individuals who carry the APOE4 allele	47
Association of cortical and subcortical microstructure with disease severity: impact on cognitive decline and language impairments in frontotemporal lobar degeneration	47
The association of circulating endocannabinoids with neuroimaging and blood biomarkers of neuro-injury	47
Tau-related grey matter network breakdown across the Alzheimer’s disease continuum	47
High-intensity walking in midlife is associated with improved memory in physically capable older adults	47
The relation of a cerebrospinal fluid profile associated with Alzheimer’s disease with cognitive function and neuropsychiatric symptoms in sporadic cerebral amyloid angiopathy	46
Impact of APOE ε4 and ε2 on plasma neurofilament light chain and cognition in autosomal dominant Alzheimer’s disease	45
Exploring easily accessible neurophysiological biomarkers for predicting Alzheimer’s disease progression: a systematic review	45
Early activation of Toll-like receptor-3 reduces the pathological progression of Alzheimer’s disease in APP/PS1 mouse	45
Alzheimer’s polygenic risk scores, APOE, Alzheimer’s disease risk, and dementia-related blood biomarker levels in a population-based cohort study followed over 17 years	44
Steeper memory decline after COVID-19 lockdown measures	43
ADataViewer: exploring semantically harmonized Alzheimer’s disease cohort datasets	43
Photobiomodulation in experimental models of Alzheimer’s disease: state-of-the-art and translational perspectives	43
Granulovacuolar degeneration bodies are independently induced by tau and α-synuclein pathology	42
Altered metabolic connectivity within the limbic cortico-striato-thalamo-cortical circuit in presymptomatic and symptomatic behavioral variant frontotemporal dementia	42
P-tau subgroups in AD relate to distinct amyloid production and synaptic integrity profiles	42
Issues and recommendations for the residual approach to quantifying cognitive resilience and reserve	42
Prevalence and modifiable risk factors for dementia in persons with intellectual disabilities	41
Restless leg syndrome and risk of all-cause dementia: a nationwide retrospective cohort study	41
Plasma lipidomics in early APP/PS1 female mouse model and its relationship with brain: Is it affected by the estrous cycle?	40
Genome-wide association study and polygenic risk scores of retinal thickness across the cognitive continuum: data from the NORFACE cohort	40
Profiles of subgingival microbiomes and gingival crevicular metabolic signatures in patients with amnestic mild cognitive impairment and Alzheimer’s disease	40
Association between glycemic status and all-cause mortality among individuals with dementia: a nationwide cohort study	38
Repurposing beta-3 adrenergic receptor agonists for Alzheimer’s disease: beneficial effects in a mouse model	37
Characterization of an APP/tau rat model of Alzheimer’s disease by positron emission tomography and immunofluorescent labeling	37
Synaptic vesicle glycoprotein 2 A in serum is an ideal biomarker for early diagnosis of Alzheimer’s disease	37
Association of modifiable risk factors with progression to dementia in relation to amyloid and tau pathology	36
Nonlinear changes in delayed functional network topology in Alzheimer’s disease: relationship with amyloid and tau pathology	36
A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects wi	36
Intermittent hypoxia treatment alleviates memory impairment in the 6-month-old APPswe/PS1dE9 mice and reduces amyloid beta accumulation and inflammation in the brain	36
Impact of amyloid and tau positivity on longitudinal brain atrophy in cognitively normal individuals	36
Sex-specific associations of kynurenic acid with neopterin in Alzheimer’s disease	35
Association between untreated and treated blood pressure levels and cognitive decline in community-dwelling middle-aged and older adults in China: a longitudinal study	35
ANU-ADRI scores, tau pathology, and cognition in non-demented adults: the CABLE study	35

Heat-related illness and dementia: a study integrating epidemiological and experimental evidence	34
Subjective cognitive concerns, APOE ε4, PTSD symptoms, and risk for dementia among older veterans	34
Genetic and clinical landscape of Chinese frontotemporal dementia: dominance of TBK1 and OPTN mutations	34
Dissecting neural correlates of theory of mind and executive functions in behavioral variant frontotemporal dementia	34
Anti-diabetic agents and the risks of dementia in patients with type 2 diabetes: a systematic review and network meta-analysis of observational studies and randomized controlled trials	34
Brain age as a biomarker for pathological versus healthy ageing – a REMEMBER study	34
Impact of gender on the willingness to participate in clinical trials and undergo related procedures in individuals from an Alzheimer’s prevention research cohort	33
Structural MRI profiles and tau correlates of atrophy in autopsy-confirmed CTE	33
Brain derived β-interferon is a potential player in Alzheimer’s disease pathogenesis and cognitive impairment	33
High-fat diet-induced atherosclerosis promotes neurodegeneration in the triple transgenic (3 × Tg) mouse model of Alzheimer’s disease associated with chronic platelet activation	33
Cerebrospinal fluid α-synuclein adds the risk of cognitive decline and is associated with tau pathology among non-demented older adults	33
Parsing heterogeneity within dementia with Lewy bodies using clustering of biological, clinical, and demographic data	32
Lewy Body Dementia Association’s Industry Advisory Council: proceedings of the second annual meeting	32
Impact of potential modifications to Alzheimer’s disease clinical trials in response to disruption by COVID-19: a simulation study	32
Prodromal frontotemporal dementia: clinical features and predictors of progression	32
A metagenomic study of gut viral markers in amyloid-positive Alzheimer’s disease patients	31
Neural correlates of episodic memory in adults with Down syndrome and Alzheimer’s disease	31
A biomarker-validated time scale in years of disease progression has identified early- and late-onset subgroups in sporadic Alzheimer’s disease	31
Association between Life’s Simple 7 and cerebrospinal fluid biomarkers of Alzheimer’s disease pathology in cognitively intact adults: the CABLE study	31
ApoJ/Clusterin concentrations are determinants of cerebrospinal fluid cholesterol efflux capacity and reduced levels are associated with Alzheimer’s disease	31
Anticipated reactions to learning Alzheimer’s disease biomarker results	31
Associations between proton pump inhibitors and Alzheimer’s disease: a nested case–control study using a Korean nationwide health screening cohort	31
Correction: Cortical microstructure in primary progressive aphasia: a multicenter study	30
Correction: Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial	30
Correction: Plasma apolipoprotein E levels, isoform composition, and dimer profile in relation to plasma lipids in racially diverse patients with Alzheimer’s disease and mild cognitive impairment	29
Correction: 18F-FDG PET can effectively rule out conversion to dementia and the presence of CSF biomarker of neurodegeneration: a real-world data analysis	29
Correction: Repurposed agents in the Alzheimer’s disease drug development pipeline	29
High-affinity antibodies specific to the core region of the tau protein exhibit diagnostic and therapeutic potential for Alzheimer’s disease	29
Correction: Impact of cumulative exposure to anticholinergic and sedative drugs on cognition in older adults: a memory clinic cohort study	28
Correction: Polygenic effects on the risk of Alzheimer’s disease in the Japanese population	27
Differential impairment of cerebrospinal fluid synaptic biomarkers in the genetic forms of frontotemporal dementia	27
The effects of a moderate physical activity intervention on physical fitness and cognition in healthy elderly with low levels of physical activity: a randomized controlled trial	26
Intracerebroventricular injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer’s disease dementia: a phase I clinical trial	26
Irregular word reading as a marker of semantic decline in Alzheimer’s disease: implications for premorbid intellectual ability measurement	25
Differential response to donepezil in MRI subtypes of mild cognitive impairment	25
Small vessel cerebrovascular disease is associated with cognition in prospective Alzheimer’s clinical trial participants	25
Amyloid PET imaging and dementias: potential applications in detecting and quantifying early white matter damage	25
Machine learning prediction of future amyloid beta positivity in amyloid-negative individuals	25
A peripheral signature of Alzheimer’s disease featuring microbiota-gut-brain axis markers	24
Greater baseline cortical atrophy in the dorsal attention network predicts faster clinical decline in Posterior Cortical Atrophy	24
An integrative multi-omics approach reveals new central nervous system pathway alterations in Alzheimer’s disease	24
Effect of the ABCA1 agonist CS-6253 on amyloid-β and lipoprotein metabolism in cynomolgus monkeys	24
Dementia and psychotropic medications are associated with significantly higher mortality in geriatric patients hospitalized with COVID-19: data from the StockholmGeroCovid project	24
The relationship between retinal layers and brain areas in asymptomatic first-degree relatives of sporadic forms of Alzheimer’s disease: an exploratory analysis	24
Shared genetic risk loci between Alzheimer’s disease and related dementias, Parkinson’s disease, and amyotrophic lateral sclerosis	24
Relationship between hearing impairment and dementia and cognitive function: a Mendelian randomization study	23
Prominent tauopathy and intracellular β-amyloid accumulation triggered by genetic deletion of cathepsin D: implications for Alzheimer disease pathogenesis	23
Longitudinal change in hippocampal and dorsal anterior insulae functional connectivity in subjective cognitive decline	23
Leading mediators of sex differences in the incidence of dementia in community-dwelling adults in the UK Biobank: a retrospective cohort study	23
A nonhuman primate model with Alzheimer’s disease-like pathology induced by hippocampal overexpression of human tau	23
The presence of circulating human apolipoprotein J reduces the occurrence of cerebral microbleeds in a transgenic mouse model with cerebral amyloid angiopathy	23
Mitochondrial SOS: how mtDNA may act as a stress signal in Alzheimer’s disease	23
Comparison of plasma neurofilament light and total tau as neurodegeneration markers: associations with cognitive and neuroimaging outcomes	23
Adherence to a lifestyle intervention – just a question of self-efficacy? Analysis of the AgeWell.de-intervention against cognitive decline	22
Prodromal characteristics of dementia with Lewy bodies: baseline results of the MEMENTO memory clinics nationwide cohort	22
Near-infrared light reduces β-amyloid-stimulated microglial toxicity and enhances survival of neurons: mechanisms of light therapy for Alzheimer’s disease	22
Association of antihypertensive drug target genes with alzheimer’s disease: a mendelian randomization study	22
Disparities in the participation and adherence of older adults in lifestyle-based multidomain dementia prevention and the motivational role of perceived disease risk and intervention benefits: an obse	22
Histone deacetylase inhibitors VPA and WT161 ameliorate the pathological features and cognitive impairments of the APP/PS1 Alzheimer’s disease mouse model by regulating the expression of APP secretase	22
Cognitively unimpaired individuals with a low burden of Aβ pathology have a distinct CSF biomarker profile	22
Risk of conversion to mild cognitive impairment or dementia among subjects with amyloid and tau pathology: a systematic review and meta-analysis	22
Serum phosphorylated tau protein 181 and neurofilament light chain in cognitively impaired heart failure patients	21
A deep learning MRI approach outperforms other biomarkers of prodromal Alzheimer’s disease	21
Higher performance for women than men in MRI-based Alzheimer’s disease detection	21
Societal and equity challenges for Brain Health Services. A user manual for Brain Health Services—part 6 of 6	21
Molecular insights into sex-specific metabolic alterations in Alzheimer’s mouse brain using multi-omics approach	21
Variables associated with cognitive function: an exposome-wide and mendelian randomization analysis	21
Serum and cerebrospinal fluid neurofilament light chain and glial fibrillary acid protein levels in early and advanced stages of cerebral amyloid Angiopathy	21
A multimodal precision-prevention approach combining lifestyle intervention with metformin repurposing to prevent cognitive impairment and disability: the MET-FINGER randomised controlled trial protoc	20
Equine-assisted services for people living with dementia: a systematic review	20
Associations between sex and lifestyle activities with cognitive reserve in mid-life adults with genetic risk for Alzheimer’s disease	20
Budget impact analysis of the use of Souvenaid in patients with prodromal Alzheimer’s Disease in Spain	20
Plasma phospho-tau217 as a predictive biomarker for Alzheimer’s disease in a large south American cohort	20
Predict Alzheimer’s disease using hippocampus MRI data: a lightweight 3D deep convolutional network model with visual and global shape representations	20
Diagnostic performance of plasma pTau217, pTau181, Aβ1-42 and Aβ1-40 in the LUMIPULSE automated platform for the detection of Alzheimer disease	20
Explaining the association between social and lifestyle factors and cognitive functions: a pathway analysis in the Memento cohort	20
Age of onset moderates the effects of Vascular Risk Factors on Neurodegeneration, Blood-Brain-Barrier permeability, and cognitive decline in Alzheimer’s Disease	20
Rationale for the selection of dual primary endpoints in prevention studies of cognitively unimpaired individuals at genetic risk for developing symptoms of Alzheimer’s disease	20
The accuracy and robustness of plasma biomarker models for amyloid PET positivity	20
Preclinical and first-in-human evaluation of AL002, a novel TREM2 agonistic antibody for Alzheimer’s disease	20

Combining plasma Aβ and p-tau217 improves detection of brain amyloid in non-demented elderly	20
Phenotype and imaging features associated with APP duplications	20
Investigating associations between blood metabolites, later life brain imaging measures, and genetic risk for Alzheimer’s disease	20
Recruitment across two decades of NIH-funded Alzheimer’s disease clinical trials	20
Analytical and clinical performance of eight Simoa® and Lumipulse® assays for automated measurement of plasma p-tau181 and p-tau217	20
Plasma amyloid-beta oligomer is related to subjective cognitive decline and brain amyloid status	19
Perceptions about dementia clinical trials among underrepresented populations: a nationally representative survey of U.S. dementia caregivers	19
NeuroEPO plus (NeuralCIM®) in mild-to-moderate Alzheimer’s clinical syndrome: the ATHENEA randomized clinical trial	19
Home-based transcranial alternating current stimulation (tACS) in Alzheimer’s disease: rationale and study design	19
Therapeutic implications of necroptosis activation in Alzheimer´s disease	19
Research attitudes in families of individuals with Down syndrome: importance for clinical trials	19
Association between brain amyloid deposition and longitudinal changes of white matter hyperintensities	19
Aβ42 oligomer-specific antibody ALZ-201 reduces the neurotoxicity of Alzheimer’s disease brain extracts	19
Predicting progression from subjective cognitive decline to mild cognitive impairment or dementia based on brain atrophy patterns	19
Impact of effective connectivity within the Papez circuit on episodic memory: moderation by perivascular space function	19
Plasma biomarkers of amyloid, tau, axonal, and neuroinflammation pathologies in dementia with Lewy bodies	19
CEST imaging combined with 1H-MRS reveal the neuroprotective effects of riluzole by improving neurotransmitter imbalances in Alzheimer’s disease mice	19
Performance of the plasma Aβ42/Aβ40 ratio, measured with a novel HPLC-MS/MS method, as a biomarker of amyloid PET status in a DPUK-KOREAN cohort	18
APOE ε4 gene dose effect on imaging and blood biomarkers of neuroinflammation and beta-amyloid in cognitively unimpaired elderly	18
Aη-α and Aη-β peptides impair LTP ex vivo within the low nanomolar range and impact neuronal activity in vivo	18
Diagnostic and prognostic value of plasma neurofilament light and total-tau in sporadic Creutzfeldt-Jakob disease	18
Evaluation of cerebrospinal fluid glycoprotein NMB (GPNMB) as a potential biomarker for Alzheimer’s disease	18
Evaluating the inter-species transmission risk of amyloid beta peptide aggregates via ingestion	18
Longitudinal validation of cognitive reserve proxy measures: a cohort study in a rural Chinese community	18
Association of oxidative stress and inflammatory metabolites with Alzheimer’s disease cerebrospinal fluid biomarkers in mild cognitive impairment	18
Serum zinc levels and in vivo beta-amyloid deposition in the human brain	18
Central autonomic network dysfunction and plasma Alzheimer’s disease biomarkers in older adults	18
Rationale and design of the BeyeOMARKER study: prospective evaluation of blood- and eye-based biomarkers for early detection of Alzheimer’s disease pathology in the eye clinic	18
Amyloid deposition and its association with depressive symptoms and cognitive functions in late-life depression: a longitudinal study using amyloid-β PET images and neuropsychological measurements	18
Associations between genetically predicted plasma protein levels and Alzheimer’s disease risk: a study using genetic prediction models	17
Proof-of-concept recall-by-genotype study of extremely low and high Alzheimer’s polygenic risk reveals autobiographical deficits and cingulate cortex correlates	17
Quantification of SNAP-25 with mass spectrometry and Simoa: a method comparison in Alzheimer’s disease	17
Serum neurofilament light chain level as a predictor of cognitive stage transition	17
Serum Thioredoxin-80 is associated with age, ApoE4, and neuropathological biomarkers in Alzheimer’s disease: a potential early sign of AD	17
Brain connectivity and metacognition in persons with subjective cognitive decline (COSCODE): rationale and study design	17
Identifying novel genetic variants for brain amyloid deposition: a genome-wide association study in the Korean population	17
Diagnostic performance of automated plasma amyloid-β assays combined with pre-analytical immunoprecipitation	17
The age-specific comorbidity burden of mild cognitive impairment: a US claims database study	17
The neural substrates of transdiagnostic cognitive-linguistic heterogeneity in primary progressive aphasia	17
Cognitive composites for genetic frontotemporal dementia: GENFI-Cog	17
Combining tau-PET and fMRI meta-analyses for patient-centered prediction of cognitive decline in Alzheimer’s disease	17
A comparison between tau and amyloid-β cerebrospinal fluid biomarkers in chronic traumatic encephalopathy and Alzheimer disease	17
Dynamic reciprocal relationships between cognitive and functional declines along the Alzheimer’s disease continuum in the prospective COGICARE study	16
Spatial navigation is associated with subcortical alterations and progression risk in subjective cognitive decline	16
Neuropsychological test performance of former American football players	16
Baseline [18F]GTP1 tau PET imaging is associated with subsequent cognitive decline in Alzheimer’s disease	16
Performance of plasma Aβ42/40, measured using a fully automated immunoassay, across a broad patient population in identifying amyloid status	16
The circadian rest-activity pattern predicts cognitive decline among mild-moderate Alzheimer’s disease patients	16
Higher levels of myelin are associated with higher resistance against tau pathology in Alzheimer’s disease	16
Deletion of Abi3/Gngt2 influences age-progressive amyloid β and tau pathologies in distinctive ways	16
Age, vascular disease, and Alzheimer’s disease pathologies in amyloid negative elderly adults	16
Functional gradients of the medial parietal cortex in a healthy cohort with family history of sporadic Alzheimer’s disease	16
Model-based stratification of progression along the Alzheimer disease continuum highlights the centrality of biomarker synergies	16
Choroid and choriocapillaris changes in early-stage Parkinson’s disease: a swept-source optical coherence tomography angiography-based cross-sectional study	16
Cancer research provides a model for advancing clinical trials in dementia in the era of disease-modifying Alzheimer’s-type dementia therapies	15
Tau levels are higher in objective subtle cognitive decline but not subjective memory complaint	15
Correction: Neuron‑derived extracellular vesicles in blood reveal effects of exercise in Alzheimer’s disease	15
A pilot study to evaluate the effect of CT1812 treatment on synaptic density and other biomarkers in Alzheimer’s disease	15
Human in vivo evidence of associations between herpes simplex virus and cerebral amyloid-beta load in normal aging	15
Imipramine and olanzapine block apoE4-catalyzed polymerization of Aβ and show evidence of improving Alzheimer’s disease cognition	15
Frontotemporal structure preservation underlies the protective effect of lifetime intellectual cognitive reserve on cognition in the elderly	15
High cognitive reserve attenuates the risk of dementia associated with cardiometabolic diseases	15
Serum immunoglobulins and biomarkers of dementia: a population-based study	15
Diagnostic accuracy of research criteria for prodromal frontotemporal dementia	15
In vivo cortical diffusion imaging relates to Alzheimer’s disease neuropathology	15
The role of perfusion, grey matter volume and behavioural phenotypes in the data-driven classification of cognitive syndromes	15
Development and clinical validation of CT-based regional modified Centiloid method for amyloid PET	14
Subclinical epileptiform activity in the Alzheimer continuum: association with disease, cognition and detection method	14
Age, sex and Alzheimer’s disease: a longitudinal study of 3xTg-AD mice reveals sex-specific disease trajectories and inflammatory responses mirrored in postmortem brains from Alzheimer’s patients	14
Different associations between body mass index and Alzheimer’s markers depending on metabolic health	14
Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study	14
Hormone therapy is associated with lower Alzheimer’s disease tau biomarkers in post-menopausal females -evidence from two independent cohorts	14
Cognitive impact of multidomain intervention and omega 3 according to blood Aβ42/40 ratio: a subgroup analysis from the randomized MAPT trial	14
The impact of kidney function on plasma neurofilament light and phospho-tau 181 in a community-based cohort: the Shanghai Aging Study	14
Systematic review: fluid biomarkers and machine learning methods to improve the diagnosis from mild cognitive impairment to Alzheimer’s disease	14
Health-related quality of life in subjective cognitive decline and mild cognitive impairment: a longitudinal cohort analysis	14
Correction: Applicability of in vivo staging of regional amyloid burden in a cognitively normal cohort with subjective memory complaints: the INSIGHT-preAD study	14
Pathway-based network medicine identifies novel natural products for Alzheimer’s disease	14
Cerebral Aβ deposition precedes reduced cerebrospinal fluid and serum Aβ42/Aβ40 ratios in the AppNL−F/NL−F knock-in mouse model of Alzheimer’s disease	14
Correction: Italian adaptation of the Uniform Data Set Neuropsychological Test Battery (I‑UDSNB 1.0): development and normative data	14
Feasibility and therapeutical potential of local intracerebral encapsulated cell biodelivery of BDNF to AppNL−G−F knock-in Alzheimer mice	14
Understanding machine learning applications in dementia research and clinical practice: a review for biomedical scientists and clinicians	14
Apolipoprotein E imbalance in the cerebrospinal fluid of Alzheimer’s disease patients	14
Correction to: Psychotherapeutic interventions in individuals at risk for Alzheimer’s dementia: a systematic review	14
Delta-opioid receptor signaling alleviates neuropathology and cognitive impairment in the mouse model of Alzheimer’s disease by regulating microglia homeostasis and inhibiting HMGB1 pathway	14
Baseline cognition is the best predictor of 4-year cognitive change in cognitively intact older adults	14
Clinical implications of head trauma in frontotemporal dementia and primary progressive aphasia	13
Performance of plasma p-tau217 for the detection of amyloid-β positivity in a memory clinic cohort using an electrochemiluminescence immunoassay	13
Aquaporin-4 cerebrospinal fluid levels are higher in neurodegenerative dementia: looking at glymphatic system dysregulation	13
The Alzheimer’s disease drug development landscape	13
Identification of methylation-regulated genes modulating microglial phagocytosis in hyperhomocysteinemia-exacerbated Alzheimer’s disease	13
Investigating the relationship between BMI across adulthood and late life brain pathologies	13
Paroxysmal slow wave events are associated with cognitive impairment in patients with obstructive sleep apnea	13
Whole-brain modeling of the differential influences of amyloid-beta and tau in Alzheimer’s disease	13
Mapping the long-term delayed recall-based cortex-hippocampus network constrained by the structural and functional connectome: a case-control multimodal MRI study	13